The expression of circ_0090049 in hepatocellular carcinoma and the molecular regulation mechanism of other biological functions.
Animals
Carcinoma, Hepatocellular
/ pathology
Cell Movement
/ physiology
Cell Proliferation
/ physiology
Female
Gene Knockdown Techniques
Humans
Liver Neoplasms
/ pathology
Mice
Mice, Inbred BALB C
MicroRNAs
/ metabolism
RNA, Circular
/ metabolism
RNA, Small Interfering
/ metabolism
Ubiquitin-Conjugating Enzymes
/ physiology
Up-Regulation
Xenograft Model Antitumor Assays
Journal
Anti-cancer drugs
ISSN: 1473-5741
Titre abrégé: Anticancer Drugs
Pays: England
ID NLM: 9100823
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
9
10
2021
medline:
9
3
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in liver cancer. Circular RNA_0090049 (circ_0090049) has been shown to be involved in the advance of HCC. However, the interaction between circ_0090049 and microRNA (miRNA) in HCC has not been studied. Quantitative real-time PCR was used to detect the expression of related genes. Through detection of cell proliferation, migration, invasion, and rate of tumor sphere formation, the capping experiment was carried out to verify the regulatory relationship between miRNA and circ_0090049 or circ_0090049 and ubiquitin-conjugating enzyme E2 T (UBE2T). The expression of related proteins was detected by Western blotting. The interaction of miRNA with circ_0090049 or UBE2T was notarized by Dual-luciferase reporter assay. Xenotransplantation experiments confirmed the function of circ_0090049 in vivo. Circ_0090049 and UBE2T were upregulated in liver cancer. Silencing circ_0090049 reduced the proliferation, migration, invasion, and tumor spheroid formation rate of Huh7 and HCCLM3 cells. MiR-605-5p and miR-548c-3p were identified as targets of circ_0090049, and UBE2T was the target of miR-605-5p and miR-548c-3p. Anti-miR-605-5p, anti-miR-548c-3p or UBE2T overexpression restored the inhibitory effect of circ_0090049 knockdown on HCC cells. Animal experiments confirmed the antitumor effect of silence circ_0090049. Circ_0090049 regulates the expression of UBE2T by regulating miR-605-5p or miR-548c-3p, thereby promoting the development of HCC cells.
Identifiants
pubmed: 34620742
doi: 10.1097/CAD.0000000000001100
pii: 00001813-202201000-00006
doi:
Substances chimiques
MIRN548 microRNA, human
0
MIRN605 microRNA, human
0
MicroRNAs
0
RNA, Circular
0
RNA, Small Interfering
0
UBE2T protein, human
EC 2.3.2.23
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-60Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014; 11:45–54.
Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009; 6:159–169.
Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther 2017; 173:106–117.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674–687.
Ge S, Huang D. Systemic therapies for hepatocellular carcinoma. Drug Discov Ther 2015; 9:352–362.
Arnaiz E, Sole C, Manterola L, Iparraguirre L, Otaegui D, Lawrie CH. CircRNAs and cancer: biomarkers and master regulators. Semin Cancer Biol 2019; 58:90–99.
Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013; 495:333–338.
Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. Mol Cancer 2017; 16:58.
Ding B, Fan W, Lou W. hsa_circ_0001955 Enhances In Vitro Proliferation, Migration, and Invasion of HCC Cells through miR-145-5p/NRAS Axis. Mol Ther Nucleic Acids 2020; 22:445–455.
Li MF, Li YH, He YH, Wang Q, Zhang Y, Li XF, et al. Emerging roles of hsa_circ_0005075 targeting miR-431 in the progress of HCC. Biomed Pharmacother 2018; 99:848–858.
Xie B, Zhao Z, Liu Q, Wang X, Ma Z, Li H. CircRNA has_circ_0078710 acts as the sponge of microRNA-31 involved in hepatocellular carcinoma progression. Gene 2019; 683:253–261.
Xiong DD, Feng ZB, Lai ZF, Qin Y, Liu LM, Fu HX, et al. High throughput circRNA sequencing analysis reveals novel insights into the mechanism of nitidine chloride against hepatocellular carcinoma. Cell Death Dis 2019; 10:658.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597–610.
Melo SA, Esteller M. Disruption of microRNA nuclear transport in human cancer. Semin Cancer Biol 2014; 27:46–51.
Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res 2013; 73:5609–5612.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495:384–388.
Liao Y, Cao L, Wang F, Pang R. miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer. J Cell Biochem 2020; 121:779–787.
Jin J, Liu H, Jin M, Li W, Xu H, Wei F. Silencing of hsa_circ_0101145 reverses the epithelial-mesenchymal transition in hepatocellular carcinoma via regulation of the miR-548c-3p/LAMC2 axis. Aging (Albany NY) 2020; 12:11623–11635.
Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D’Andrea AD, Dutta A. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell 2006; 23:589–596.
Miles JA, Frost MG, Carroll E, Rowe ML, Howard MJ, Sidhu A, et al. The fanconi anemia DNA repair pathway is regulated by an interaction between ubiquitin and the E2-like fold domain of FANCL. J Biol Chem 2015; 290:20995–21006.
Yu H, Xiang P, Pan Q, Huang Y, Xie N, Zhu W. Ubiquitin-conjugating enzyme E2T is an independent prognostic factor and promotes gastric cancer progression. Tumour Biol 2016; 37:11723–11732.
Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu C, et al. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging (Albany NY) 2020; 12:10275–10289.
Qiao L, Dong C, Ma B. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regulating the PI3K/AKT signaling pathway. J Recept Signal Transduct Res 2021; 12:1–9.
Wu M, Li X, Huang W, Chen Y, Wang B, Liu X. Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal cancer progression by facilitating ubiquitination and degradation of p53. Clin Res Hepatol Gastroenterol 2021; 45:101493.
Ho NPY, Leung CON, Wong TL, Lau EYT, Lei MML, Mok EHK, et al. The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression. Cell Death Dis 2021; 12:148.
Kim DK, Song B, Han S, Jang H, Bae SH, Kim HY, et al. Phosphorylation of OCT4 serine 236 inhibits germ cell tumor growth by inducing differentiation. Cancers (Basel) 2020; 12:E2601.
Kim HY, Lee BI, Jeon JH, Kim DK, Kang SG, Shim JK, et al. Gossypol suppresses growth of temozolomide-resistant glioblastoma tumor spheres. Biomolecules 2019; 9:E595.
Lin G, Wang S, Zhang X, Wang D. Circular RNA circPLK1 promotes breast cancer cell proliferation, migration and invasion by regulating miR-4500/IGF1 axis. Cancer Cell Int 2020; 20:593.
Hou W, Zhang Y. Circ_0025033 promotes the progression of ovarian cancer by activating the expression of LSM4 via targeting miR-184. Pathol Res Pract 2021; 217:153275.
Li X, Song L, Wang B, Tao C, Shi L, Xu M. Circ0120816 acts as an oncogene of esophageal squamous cell carcinoma by inhibiting miR-1305 and releasing TXNRD1. Cancer Cell Int 2020; 20:526.
Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer 2019; 18:119.
Yin H, Wang X, Zhang X, Zeng Y, Xu Q, Wang W, et al. UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. Cancer Lett 2020; 494:121–131.